Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
USA116th CongressHR-3772| House
| Updated: 7/17/2019
Scott H. Peters
Democratic Representative
California
Cosponsors (24)
David Loebsack (Democratic)Tim Burchett (Republican)Guy Reschenthaler (Republican)Lisa Blunt Rochester (Democratic)Gregory F. Murphy (Republican)Darren Soto (Democratic)Terri A. Sewell (Democratic)Bobby L. Rush (Democratic)Jackie Walorski (Republican)Donald M. Payne (Democratic)Ted Lieu (Democratic)Alan S. Lowenthal (Democratic)Ann M. Kuster (Democratic)Harley Rouda (Democratic)Dean Phillips (Democratic)Raja Krishnamoorthi (Democratic)John H. Rutherford (Republican)Bonnie Watson Coleman (Democratic)James P. McGovern (Democratic)Seth Moulton (Democratic)Elissa Slotkin (Democratic)Bill Posey (Republican)Susan W. Brooks (Republican)George Holding (Republican)
Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2020 and as adjusted based on a specified fee schedule factor in each year thereafter.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Health
Drug therapyHealth care costs and insuranceHealth technology, devices, suppliesHome and outpatient careMedical tests and diagnostic methodsMedicare
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
USA116th CongressHR-3772| House
| Updated: 7/17/2019
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2020 and as adjusted based on a specified fee schedule factor in each year thereafter.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Scott H. Peters
Democratic Representative
California
Cosponsors (24)
David Loebsack (Democratic)Tim Burchett (Republican)Guy Reschenthaler (Republican)Lisa Blunt Rochester (Democratic)Gregory F. Murphy (Republican)Darren Soto (Democratic)Terri A. Sewell (Democratic)Bobby L. Rush (Democratic)Jackie Walorski (Republican)Donald M. Payne (Democratic)Ted Lieu (Democratic)Alan S. Lowenthal (Democratic)Ann M. Kuster (Democratic)Harley Rouda (Democratic)Dean Phillips (Democratic)Raja Krishnamoorthi (Democratic)John H. Rutherford (Republican)Bonnie Watson Coleman (Democratic)James P. McGovern (Democratic)Seth Moulton (Democratic)Elissa Slotkin (Democratic)Bill Posey (Republican)Susan W. Brooks (Republican)George Holding (Republican)
Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug therapyHealth care costs and insuranceHealth technology, devices, suppliesHome and outpatient careMedical tests and diagnostic methodsMedicare